Latest News Archive
Please select Category, Year, and then Month to display items
The University of the Free State (UFS) wishes to confirm that the following financial concessions have been made to enable students to register for the 2024 academic year:
- Students with confirmed NSFAS funding:
- Students with a confirmed National Student Financial Aid Scheme (NSFAS) funding allocation for 2024 with a debt of R20 000 and less may register fully without making any payments.
- First-time entering students (FTENS) with a confirmed NSFAS funding allocation for 2024 may register fully without any payments.
- Students with a confirmed NSFAS funding allocation for 2024 with a debt of R30 000 and less may register provisionally and pay the required fees* for provisional registration.
- South African self-paying (NON-NSFAS) students:
- SA students with a debt of up to R500 may register fully without making any payments.
- SA students with a debt of up to R30 000 may register provisionally and pay the required fees* for provisional registration.
- FTENS not on UFS funded list:
- Students who are not on the funded list but report that they have been approved on their portal must contact our
Financial Aid Offices urgently so that the university can escalate to NSFAS.
The university will have continuous engagement with the National Financial Aid Scheme (NSFAS) to resolve outstanding matters. The university’s Financial Working Group (FWG) will meet regularly to determine how it can best assist students taking into consideration the financial constraints of the university.
New research informs improved treatment of brain inflammation
2017-10-13
Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish
Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology.
Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.
Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs.
Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology